Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?
A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
No genetic correlation was seen with Merck & Co's CETP inhibitor, but Dalcor believes that things will be different for dalcetrapib.
As approval decisions near, further data fail to answer lingering questions about Esperion's bempedoic acid and Amarin's Vascepa.
Will the Apple Heart Study allow early detection of arrhythmias, or drive the worried well to doctors unnecessarily? For Irhythm Technologies, either is a good outcome.
Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
As pressure builds on the German group to explain how it will replace expiring blockbusters, executives lay out a preference for early-stage collaborations and insist…